# Sustainable improvement of interprofessional care for better resident outcomes: protocol for the INTERSCALE hybrid type III effectiveness cluster-randomized trial comparing individualized and collaborative delivery of an evidence-based care model for long-term care

**Authors:** Franziska Zúñiga, Lea Saringer-Hamiti, Flaka Siqeca, Sarah Holzer, Raphaëlle-Ashley Guerbaai, Thekla Brunkert, Farah Islam, Jana Bartáková, Anja Orschulko, Sandra Staudacher, Reto W. Kressig, Andreas Zeller, Christine Serdaly, Nathalie I. H. Wellens, Sabina M. De Geest, Vanessa Litschgi, Natalie Zimmermann, Michael Simon

PMC · DOI: 10.1186/s13012-026-01489-0 · 2026-02-20

## TL;DR

This study tests whether a group-based approach to implementing a nurse-led care model in long-term care facilities is as effective as a one-on-one approach in reducing hospital transfers.

## Contribution

The study introduces a scalable, collective implementation strategy for an evidence-based care model in long-term care.

## Key findings

- The collective implementation approach may achieve non-inferior fidelity to the INTERCARE model.
- The study will compare cost-effectiveness and organizational outcomes between individualized and collective support methods.
- Results may inform scalable strategies for improving care in long-term care facilities.

## Abstract

Over recent decades, multifaceted nurse-led care models have been developed to reduce unplanned hospital transfers from long-term care facilities (LTCFs). In Switzerland, the INTERCARE model has demonstrated effectiveness, with core components including deployment of nurses in expanded roles (INTERCARE nurses), evidence-based communication tools, and advance care planning. However, resource-intensive implementation strategies such as 1:1 support meetings for model implementers pose challenges for scale-up, underscoring the need for more scalable implementation support. The INTERSCALE study compares two modes of delivering implementation support—an individualized and a collective-oriented approach—testing the hypothesis that the latter achieves non-inferior fidelity to the INTERCARE model and comparable reductions in unplanned hospital transfers at the LTCF level. Secondary aims are to compare implementation (acceptability, feasibility), economic (costs, cost-effectiveness), clinical (unplanned transfers), and organizational (staff absences, turnover) outcomes.

This non-inferiority, effectiveness–implementation hybrid type III trial uses a cluster-randomized controlled design, with LTCFs as the unit of randomization. Forty German-speaking LTCFs in Switzerland (≥20 long-term care beds; cantonal accreditation) will be randomized (1:1) after formal consent to either individualized or collective implementation support, without blinding of LTCFs or the research team. In the individualized arm (20 LTCFs), leadership receives 1:1 support meetings, and INTERCARE nurses receive 1:1 coaching, mirroring the original INTERCARE trial. In the collective arm (20 LTCFs), leadership support and INTERCARE nurse coaching are delivered in group formats involving several LTCFs/INTERCARE nurses together at two-monthly intervals. The primary outcome is LTCF-level fidelity to the INTERCARE core components, analyzed with a binomial generalized linear mixed model including a random LTCF effect. Non-inferiority of the collective mode will be concluded if the lower bound of its 95% confidence interval for fidelity is within 15% of the individualized mode. A 12-month cost-effectiveness analysis from a multi-stakeholder perspective (LTCFs and research group) will estimate the incremental cost-effectiveness ratio using differences in implementation costs and unplanned transfers between arms; secondary outcomes include unplanned transfers, staff turnover, and absences.

This type III hybrid cluster trial addresses a key scaling challenge in implementation science by testing less resource-intensive implementation strategies for disseminating an evidence-based care model across LTCFs in routine practice.

Prospectively registered on June 25, 2024, at ClinicalTrials.gov nr. NCT06473051.

The online version contains supplementary material available at 10.1186/s13012-026-01489-0.

## Full-text entities

- **Diseases:** ACP (MESH:C562856), ERIC (MESH:D009402)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13032367/full.md

---
Source: https://tomesphere.com/paper/PMC13032367